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Drug-induced adverse reactions represent major health problems, with the skin being one of the
most common targets. Approximately 2% of all drug-induced skin reactions are considered serious.
StevenseJohnson syndrome/toxic epidermal necrolysis corresponds to rare and acute life-threatening
mucocutaneous reactions characterized by extensive necrosis and epidermal detachment. This review
focuses on the management of these severe cutaneous reactions in the French Referral Center for Toxic
Bullous Diseases. Early referral to a specialized unit, early diagnosis of severe cutaneous adverse re-
actions, prompt withdrawal of the culprit drug, improved symptomatic management, and speciﬁc
dermatological care have contributed to better survival in the past 10 years and also has limited sequelae.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Drug-induced adverse reactions represent major health prob-
lems,1 with the skin being one of the most common targets.2
Approximately 2% of all drug-induced skin reactions are consid-
ered serious according to the World Health Organization deﬁni-
tion.3 In 1994, Roujeau and Stern4 estimated that one in every
1000 hospitalized patients experienced severe cutaneous adverse
reactions (SCARs), including StevenseJohnson syndrome/toxic
epidermal necrolysis (SJS/TEN), drug reactions with eosinophilia
and systemic symptoms, and acute generalized exanthematous
pustulosis. The SJS/TEN corresponds to rare and acute life-
threatening mucocutaneous reactions characterized by extensive
necrosis leading to epidermal detachment. The incidence of SJS/
TEN is approximately one to two cases/million people/year.5,6
Overall, in-hospital European mortality is estimated to be
greater than 22%.7
This review focuses on the management of these severe cuta-
neous reactions in the French Referral Center for Toxic Bullous
Diseases, which was established in 2004 by the French Ministry of
Health.y, 51 Avenue du Maréchal de
. Valeyrie-Allanore).
iwanese Dermatological AssociatioEarly diagnosis
Early diagnosis of SJS/TEN based on initial clinical symptoms is
often difﬁcult and delayed. However, prompt recognition, speciﬁc
transfer, and early withdrawal of the culprit agent(s) may help in
decreasing mortality.8
Clinically, SJS/TEN begins 4e28 days after starting drug(s)7 and
may continue for a few days even after the drug(s) has been
withdrawn. For approximately 30% of cases, no causative drug is
identiﬁed, and for 15%, drug responsibility is considered unlikely.9
General physical deterioration; fever; ﬂu-like syndrome; ocular
symptoms; ear, nose, and throat events; and skin pain precede
dermatological manifestations and are key signs that contribute to
early diagnosis. Atypical target lesions with a dark center may often
be observed, without the typical three concentric rings of erythema
multiforme major, mainly localized on the trunk and proximal
limbs. Lesions evolve into conﬂuent ﬂaccid blisters leading to
extensive erythema and skin detachment. Based on the extent of
body surface area (BSA) involved, the disease is classiﬁed as fol-
lows: SJS, <10% BSA; SJS/TEN, 10e30% BSA; and TEN, >30% BSA.6
The Nikolsky sign is a helpful clinical indicator of epidermal nec-
rolysis. More than 80% of cases involve at least two mucous
membranes, leading to painful erosions and can often precede skin
lesions.10
The SJS/TEN visceral involvements include elevated liver and/or
renal enzymes or bronchial and digestive-tract epithelial necrosis
with sloughing of epithelia similar to epidermal detachment.11,12n. Published by Elsevier Taiwan LLC. All rights reserved.
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(IgA) bullous dermatosis, erythema multiforme major, pemphigus,
generalized bullous ﬁxed drug eruption, staphylococcal scaled-skin
syndrome and, depending on the context, acute graft-versus-host
disease and methotrexate-related skin necrosis, etc.
When to suspect the diagnosis
No speciﬁc score or test is available for SJS/TEN diagnosis. The
diagnosis mainly relies on a broad spectrum of the following clin-
ical signs or symptoms: (1) severe prodromal illness: fever up to
39C, malaise, mucous membrane pain; (2) clinical examination:
severe skin pain, mucous membrane erosions, atypical targets as
described earlier, vesicles, and/or bullous lesions, Nikolsky sign;
and (3) rapidly extensive rash and/or mucous membrane lesions.
Diagnosis can be secondarily conﬁrmed based on results of histo-
logical tests.13
The association of these three signs should lead to contacting
the referral center for a transfer and beginning the best supportive
care, which is explained in the “Management in a Dermatological
Intensive Care Unit” section.
How to manage the disease initially
Management at the acute stage is sequential as follows (Table 1):
(1) Evaluation of the severity and prognosis of the disease [SCORe ofTable 1 Mandatory indications to correctly refer a patient with StevenseJohnson
syndrome/toxic epidermal necrolysis in an emergency to a dermatological
intensive care unit.
Clinical examination  Vitals: blood pressure, pulse/minute,
temperature, SaO2, and respiratory
frequency
 Evaluation of body surface area
involved (Wallace’s Rule of Nines)
 Respiratory involvement
Biological investigations  Full blood count
 Urea and electrolytes, bicarbonate,
glycemia
 Blood gas (systematic analysis)
 Chest X-ray
 Photographs
Initial symptomatic management  Peripheral venous access
 Urinary catheter (with urogenital
involvement and for evaluation of
renal function)
 Oxygen therapy, if necessary
 Fluid resuscitation
 Parenteral pain management
 Isolated and heating room
 No immunomodulating treatment
before agreement of the referral team
Discontinue the offending agent
without delay
 Molecule usually introduced be-
tween 4 and 28 days before disease
onset
 Maintain nonsuspected drugs (taken
at least 2 months without any
adverse effect)
 With major treatment: replace the
molecule with another from another
pharmacological class
SCORTEN evaluation13,14
(1 point is attributed to each
of the following)
Life threatening if total score 1
 Age >40 years
 Presence of malignancy
 Heart rate >120 beats/minute
 Percentage of epidermal detachment
>10%
 Urea level >10 mmol/L
 Serum glucose >14 mmol/L
 Bicarbonate level <20 mmol/L
Contact referral center and
organize transfer
 Intensive care unit transfer with
SCORTEN score >1Toxic Epidermal Necrosis (SCORTEN) severity-of-illness scale, lung
involvement]14e16; (2) Prompt identiﬁcation of the culprit drug;
and (3) Rapid initiation of supportive care.
Management in a dermatological intensive care unit
Early referral to a speciﬁc unit is associatedwith good survival.4 The
mean delay between disease onset and management in our
department is estimated to be>3.5 days17 and the overall mortality
rate was >8% between 2005 and 2009, irrespective of the per-
centage of BSA involved (unpublished data). Until now, treatment
of SJS/TEN has been mainly symptomatic, consisting of speciﬁc
nursing care, maintenance of ﬂuid and electrolyte balance, and
nutritional support.
Early withdrawal of the culprit drug
Accurately documenting the medication history during the previ-
ous 2 months is mandatory to determine the index day, which is
deﬁned as the date of onset of SCAR-related symptoms or signs that
progressed within 3 days.7e9 The suspected drug(s) should be
withdrawn as soon as possible after establishing the precise chro-
nology of each drug. The usual practice is to maintain drugs with
long-term use and discontinue all drugs that are nonessential.
However, in some cases, the risk versus beneﬁt for each drug must
be weighed and whether a similar acting but non-cross-reactive
drug is available as a substitute should be investigated. An algo-
rithm for assessment of drug causality in epidermal necrolysis
(ALDEN or algorithm of drug causality for EN), speciﬁcally devel-
oped for this disease, is systematically followed.9
Symptomatic management
Patients transferred to a dermatological intensive care unit are
managed symptomatically as follows: (1) SJS/TEN is associatedwith
signiﬁcant ﬂuid loss due to evaporation from erosions, edema, and
blisters, resulting in hypovolemia and electrolyte imbalance. Fluid
replacement must be started as soon as possible and adjusted daily.
Peripheral venous access is preferentially established on nonle-
sional skin. Central venous lines are not routinely inserted because
of septic risk.18 (2) Patients are in a special intensive care room
(Figure 1). Environmental temperature should be maintained at
28 C to decrease energy consumption. (3) Enteral nutritional
hypercaloric and hyperprotidic support is initiatedmost of the time
using a nasogastric tube to prevent protein loss and promote
healing. Parenteral nutrition is not recommended because it is
frequently poorly tolerated and associated with increased risk of
sepsis. (4) Antibiotic prophylaxis is not recommended. In order to
prevent the risk of sepsis, patients are carefully handled. Bacterial
and fungal cultures of skin, blood, and urine are performed at least
two times aweek. Antibiotics are initiated when clinical infection is
diagnosed or strongly suspected and conﬁrmed by a positive bac-
terial sample. (5) Standard prophylactic anticoagulation therapy is
provided. (6) Management of pain is a major point, often under-
estimated, and necessitates respiratory monitoring. Pain is sys-
tematically assessed on a 10-point visual analog scale (VAS) every 4
hours and based on the VAS score obtained, the treatment is
modiﬁed if necessary. If the VAS score is >4, morphine is initiated
by patient-controlled analgesia mechanisms.19 An intravenous (IV)
pulse of dexamethasone (1 mg/10 kg) can be added when the pa-
tient is transported for a bath.20 (7) Anxiety is systematically
evaluated by a psychiatrist and speciﬁc treatment is initiated if
necessary. (8) Systematic invasive mechanical ventilation is per-
formed only with severe sepsis or life-threatening visceral failure.
(9) Skin histology is systematically performed by direct and indirect
Figure 1 Dermatological intensive care unit room.
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differential diagnoses.Speciﬁc dermatological care
Wounds are cared for once a day, with minimal manipulation to
prevent skin detachment. Wounds are treated conservatively,
without large and aggressive skin debridement.20 Detached
epidermis acts as a natural biological dressing, which likely favors
reepithelialization.Bathing
Once a day, patients receive a bath containing a solution of chlor-
hexidine (1/5000). If bathing is not possible, the solution is sprayed
two or three times/day. A morphine IV pulse (0.1 mg/10 kg) is
recommended 30minutes before the bath and/or an equimolar mix
of oxygen and nitrogen monoxide (MEOPA) is preferred during the
bath. The water temperature is systematically controlled (between
37 and 39 C).Skin care
Blister ﬂuid is aspirated while maintaining the blister roof to pro-
tect the underlying dermis. Vaseline is systematically applied
widely over all detached skin areas. Topical sulfa-containing med-
ications should be avoided. Hydrocellular or absorbent nonadhe-
sive dressings are applied at least once a day to cover pressure
points, particularly on the back.Mucous membrane management
Ocular, oral, nasal, genitalia, anal mucosa lubricationwith emollient
is mandatory to prevent and limit adhesion formation andsequelae. Crusts are cleaned daily using an isotonic sterile sodium
chloride solution and covered with Vaseline.
Prevention of long-term ocular sequelae is a major challenge.
Eyes should be regularly examined by an ophthalmologist. Antibi-
otic eyedrops, vitamin A, and antiseptic agents are instilled every 2
hours during the acute phase; adhesions are broken down using a
glass rod at least two times a day. The mouth should be rinsed
several times a day with an antiseptic or antifungal solution.
Speciﬁc systemic treatment
A speciﬁc immunomodulating treatment for SJS/TEN is still being
debated. A number of immunosuppressive and/or anti-
inﬂammatory therapies such as corticosteroids,20,21 calcineurin
inhibitors,17,22 antitumor-necrosis-factor (TNF) therapies,23,24
IVIg,25e27 plasmapheresis,28 and cyclosphosphamide29 associated
with supportive care have been evaluated, largely in small uncon-
trolled studies.
Thalidomide
Thalidomide could have been an interesting strategy because of its
anti-TNF-a activity. Wolkenstein et al conducted a double-blind
randomized, placebo-controlled trial, which was stopped because
mortality was increased in the thalidomide group, thus suggesting
that thalidomide has a detrimental effect in the treatment of TEN.24
IVIg
A possible effect of IVIg is that Fas-mediated cell death might be
abrogated by monoclonal antibodies against the Fas ligand or the
soluble form of the Fas receptor.25 In fact, the beneﬁt-to-risk ratio of
IVIg is still debated. Bachot et al conducted a prospective mono-
centric noncomparative trial showing the lack of beneﬁt of IVIg for
mortality or progression of the disease.26
Ciclosporin
We conducted an open Phase II trial to evaluate the safety and
possible interest of antiapoptotic and immunomodulating ciclo-
sporin (3 mg/kg/day for 10 days, tapered over a month).17 The re-
sults show that ciclosporin is well tolerated. While the SCORTEN
predicted three deaths, none actually occurred (p ¼ 0.01).
Currently, if possible, based on medical history, patients receive
ciclosporin (3 mg/kg/day for 10 days). However, further prospective
studies are needed to conﬁrm the beneﬁts and the absence of
signiﬁcant adverse effects.
Follow-up
After the acute phase, SJS/TEN carries a non-negligible risk of se-
vere sequelae, especially ocular and psychiatric events.30e33 A
speciﬁc multidisciplinary approach is routinely applied for their
early detection and treatment.34 Patients are examined at least at 2,
6, and 12 months after the acute stage (Figure 2). Speciﬁc sequelae
may require monthly evaluation.
Patch testing with several suspected drugs can be proposed at 1
year, and a speciﬁc drug allergy card is used to deﬁnitively exclude
the potential causative agent(s) and all members of the same
pharmacological family but not the entire therapeutic group.
Conclusion
Prompt transfer of patients with SJS/TEN and management in a
speciﬁc expert centre such as the French Referral Center for Toxic
Patient follow-up
2, 6, and 12 months after the acute 
stage
Ophthalmologist





Figure 2 Multidisciplinary follow-up for StevenseJohnson syndrome/toxic epidermal necrolysis.
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culprit drug, and decreased mortality in these diseases. Symp-
tomatic treatment and speciﬁc nursing care are of utmost impor-
tance in preventing and limiting sequelae. In addition, systematic
long-term follow-up by an expert physician should be organized.References
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